Medicines Formulary

Reports

Drug name	NICE TAs	Comments
Revaxis		Supported with PGD
Ribociclib (Kisqali®)	TA496 - Ribociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer TA593 - Ribociclib with fulvestrant for treating hormone receptor-positive, HER2-negative, advanced breast cancer TA687 - Ribociclib with fulvestrant for treating hormone receptor-positive, HER2-negative, advanced breast cancer	For hospital use only
Riboflavin		Specialist recommendation - inherited metabolic disease.
Rigevidon		Umbrella service only
Riluzole tablets	TA20 - Guidance on the use of Riluzone (Rilutek) for the treatment of Motor Neurone Disease	ESCA
Risperidone injection		APC verdict - present status = RED (Future status = AMBER with a framework in primary care before transfer - commissioning discussion)
Risperidone liquid		ESCA
Risperidone tablets		ESCA
Rivaroxaban tablets	TA170 - Venous thromboembolism - Rivaroxaban TA335 - Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome TA256 - Atrial fibrillation (stroke prevention) - Rivaroxaban TA261 - Venous thromboembolism (treatment and long-term secondary prevention) - Rivaroxaban TA287 - Pulmonary embolism and recurrent venous thromboembolism TA607 - Rivaroxaban for preventing atherothrombotic events in people with coronary or peripheral artery disease	Amber - specialist initation following diagnosis of AF- use in line with NICE. Initiation/ recommendation by a clinician who routinely initiates anticoagulants Amber - specialist initation for the treatment and secondary prevention of DVT and/or PE - use in line with NICE. Initiation/ recommendation by a clinician who routinely initiates anticoagulants. Where this is not the patient's GP, transfer to GP should be with the support of RICaD Amber - specialist initiation for preventing adverse outcomes after acute management of ACS use in line with NICE TA335. Initiation/recommendation by a clinician who routinely initiates anticoagulants. Where this is not the patient's GP, transfer to GP should be with the support of RICaD
Rivaroxaban tablets	TA170 - Venous thromboembolism - Rivaroxaban TA607 - Rivaroxaban for preventing atherothrombotic events in people with coronary or peripheral artery disease	BSSE APC preferred agent. This recommendation must only be taken into account after a patient and prescriber have discussed all treatment options (including warfarin) and only if they have no preference about which medicine they want to use. Red use following hip and knee surgery – full course of treatment supplied on discharge

First page
Previous page
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
Next page
Last page

Drug status key

Formulary drugs are allocated a traffic light status. This provides guidance on where clinical and prescribing responsibilities lie in regard to the initiation and maintenance of prescribing.

Grey

Positive NICE TA and/or awaiting local clarification on place in therapy. Please contact your medicines optimisation team for more information.

Red

Initiation and maintenance of prescribing by specialists only.

Amber

Initiation and maintenance of prescribing by specialists and transfer to primary care prescribing when appropriate, or in primary care following a specialists recommendation. Prior to initiation some medicines may require committee agreement or a framework to support safe transfer and maintenance.

Green

Initiation and maintenance of prescribing by specialists, GPs and other qualified clinicians.

Blue

Under review at University Hospitals Birmingham NHS Foundation Trust.